TriSalus Life Sciences Inc
NASDAQ:TLSI
Gross Margin
TriSalus Life Sciences Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
T
|
TriSalus Life Sciences Inc
NASDAQ:TLSI
|
194.5m USD |
85%
|
|
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
633.6T EUR | N/A | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
164.6B USD |
18%
|
|
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
98.2B USD |
16%
|
|
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
88.3B Zac |
66%
|
|
| US |
|
Coupang Inc
F:788
|
43.8B EUR |
30%
|
|
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
44.7B USD |
74%
|
|
| US |
R
|
Reddit Inc
NYSE:RDDT
|
40.9B USD |
91%
|
|
| CH |
G
|
Galderma Group AG
SIX:GALD
|
32.2B CHF |
69%
|
|
| ID |
|
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
630.2T IDR |
42%
|
|
| US |
C
|
Circle Internet Group Inc
NYSE:CRCL
|
31.5B USD |
0%
|
TriSalus Life Sciences Inc
Glance View
TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on TriSalus Life Sciences Inc's most recent financial statements, the company has Gross Margin of 84.7%.
You don't have any saved screeners yet